FOUNTAIN HILLS, Ariz., Sept. 23 /PRNewswire/ — Sunridge
International (OTC Bulletin Board:
SNDZ) announced today that it has shipped its first order to
Ameco Medical Equipment L.L.C., its exclusive distributor for
several Middle Eastern countries. AME plans to start its
marketing rollout of Pneumatic Trabeculoplasty (PNT) throughout the
region, while simultaneously conducting a short study to gain
reimbursement approval for the PNT procedure. Once
established, the population of glaucoma sufferers waiting for
treatment can be helped.
Sunridge International’s CEO, G. Richard Smith states, “This is
an important step for our company. Our focus this year has
been expanding our distribution network worldwide, and entering the
Middle Eastern market, with the high incidence of glaucoma in its
population, can and should produce millions in revenue for our
company.”
Glaucoma is the second leading cause of blindness, affecting
over 70 million people worldwide. PNT has been proven (through
studies completed over the last 10 yrs) to be a safe, effective,
non-invasive and a cost effective alternative for treatment for
glaucoma and ocular hypertension. The 2-minute treatment has been
developed, patented, and distributed by Sunridge International,
wholly owned subsidiary, Ophthalmic International (www.oi-pnt.com).
For full details of PNT and its application, we invite you to
visit Sunridge International’s website at www.sunridgeint.com.
Forward-looking statements in this release are made pursuant to
the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties,
including without limitation, continued acceptance of the company’s
products, increased lev
‘/>”/>
